Categories
CDE Diabetes

Practice Exam: FIT Canada Recommendations for Injection Technique

The efficacy of insulin therapy is only as good as the technique used to deliver it. The Forum for Injection Technique (FIT) Canada Recommendations emphasize that correct injection technique is just as critical as the type and dose of insulin prescribed. Poor technique can lead to unexplained hypoglycemia, glycemic variability, and long-term complications.

This practice exam tests your ability to apply the “Golden Rules” of injection, manage injection site complications like lipohypertrophy, and select the appropriate delivery devices for patients of all body types.

Key Concepts Covered in This Exam:

  • Needle Selection: Understanding the evidence supporting the use of 4 mm pen needles as the safest and most effective option for all adults and children, regardless of BMI, to avoid intramuscular (IM) injections.

  • Lipohypertrophy (LH): Mastering the detection and management of “lumpy” injection sites, acknowledging that injecting into LH can reduce insulin absorption by up to 25% and cause erratic glucose levels.

  • Structured Rotation: Applying correct rotation principles—spacing injections at least 1 cm (approx. width of a finger) apart and utilizing divided zones—to preserve tissue health.

  • Single Use: Reinforcing the strict recommendation that needles and syringes are single-use devices and must be discarded immediately to prevent tip deformation, infection, and lipohypertrophy.

  • Psychological Barriers: Addressing patient fears and anxiety regarding injections to improve adherence and comfort.

1. Case: A healthcare professional is teaching a parent how to inject insulin into their anxious 7-year-old child. What strategy would be most appropriate to reduce needle anxiety?

2. How often should all components of an insulin infusion set (insulin, reservoir, and tubing) be changed?

3. A patient on insulin pump therapy develops unexplained hyperglycemia with ketones. After correcting with injection, what troubleshooting steps should be taken?

4. What is the strongest correlating factor in the development of lipohypertrophy according to research?

5. What is the recommended distance between injection sites when rotating within an anatomical area?

6. Why might non-posted (contoured) pen needle designs be preferred over conventional posted-hub designs?

7. Case: An adolescent with type 1 diabetes has poor glycemic control and admits to sometimes skipping insulin doses due to peer pressure. What is the recommended approach?

8. Case: A diabetes educator is developing a teaching plan for injection technique. According to the guidelines, what is the most critical educational priority?

9. What effect does massaging the injection site immediately before or after injection have on insulin?

10. According to FIT Canada, how should concentrated insulins (U-200, U-300, U-500) be handled regarding syringes?

11. Why is the arm NOT recommended as a preferred self-injection site?

12. Case: A child aged 5 requires insulin injections. What is the recommended needle length and technique?

13. A patient asks why they should not reuse pen needles. What is the most appropriate response based on FIT recommendations?

14. A patient using an 8-mm needle asks about the correct injection technique. What is the appropriate instruction?

15. In an institutional setting, what specific safety measure regarding injection devices is emphasized by FIT Canada?

16. What should be done if pen needles are left attached to the pen between injections?

17. A patient with type 2 diabetes expresses psychological resistance to starting insulin therapy. According to FIT recommendations, what is the most appropriate approach?

18. Case: A patient using a GLP-1 receptor agonist pen asks if they need to prime the pen before each injection. What is the correct guidance?

19. Case: A patient with diabetes is switching from injecting into a lipohypertrophic site to a healthy site. What counseling should be provided?

20. What is the average skin thickness (epidermis and dermis) regardless of age, BMI, gender, or race?

21. Case: A patient using an insulin pump develops recurrent unexplained hyperglycemia and increased skin irritation at infusion sites. What is the likely issue and solution?

22. What is the recommended storage temperature for unopened insulin vials and cartridges?

23. Case: A patient reports unexplained hypoglycemic episodes despite consistent insulin dosing. Upon examination, you discover lipohypertrophic tissue at their usual injection site. What is the most likely explanation?

24. Case: A 4-month-old infant is diagnosed with neonatal diabetes requiring insulin therapy. What is the most appropriate infusion site consideration?

25. Case: An elderly patient with cognitive impairment requires insulin therapy. What is the preferred delivery device according to FIT recommendations?

26. Case: A 55-year-old person with obesity (BMI 38 kg/m²) is initiating insulin therapy. They ask if they need a longer needle due to their body size. What is the most appropriate response?

27. When using cloudy insulin (NPH or premixed), what is the recommended technique for re-suspension?

28. Case: A patient taking >50 units of regular or NPH insulin per injection asks about splitting the dose. What is the clinical rationale for this recommendation?

29. What percentage of individuals with lipohypertrophy has been observed in international trials?

30. Case: An insulin pump user develops a “pump bump” (localized bump at insertion point) with redness. What is the most likely cause and recommended action?

31. Case: A woman in her third trimester of pregnancy asks where she should inject her insulin. What is the most appropriate recommendation?

32. A healthcare professional asks about the proper technique for palpating injection sites to detect lipohypertrophy. What is the correct technique?

33. Case: A clinical team is debating whether to use alcohol swabs before insulin injections in a community setting. Based on FIT guidelines, what is the correct recommendation?

34. According to FIT Canada, what is the recommended pen needle length suitable for all people with diabetes, regardless of BMI?

35. Research shows that after avoiding lipohypertrophic sites for 3-6 months, what outcome may be observed?

36. What is the minimum duration a patient should count after depressing the insulin pen injection dose knob before withdrawing the needle?

37. According to FIT Canada, which injection area offers the most consistent absorption of regular and NPH insulin?

38. Case: A lean male patient (BMI 22 kg/m²) reports injecting into his thigh using a 6-mm needle at 90 degrees. He frequently experiences rapid-onset hypoglycemia. What is the most likely cause?

39. Case: A patient asks why injection into the buttocks results in slower insulin absorption. What is the scientific explanation?

40. Lipohypertrophy is best described as: